Ken Griffin
CBIO

Ken Griffin’s Crescent Biopharma CBIO Stock Holding History

Ken Griffin’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-590
Closed -$12.4K – 13458
2025
Q1 		$12.4K Buy
590
+80
+16% +$2.14K ﹤0.01% 13449
2024
Q4 		$12.7K Buy
+510
New +$13.9K ﹤0.01% 13485
2024
Q3 		– Sell
-494
Closed -$13.9K – 14582
2024
Q2 		$13.9K Sell
494
-75
-13% -$7.8K ﹤0.01% 12913
2024
Q1 		$171K Buy
569
+511
+881% +$153K ﹤0.01% 10572
2023
Q4 		$13.7K Buy
+58
New +$9.02K ﹤0.01% 12918
2023
Q3 		– Sell
-160
Closed -$27.8K – 14592
2023
Q2 		$27.8K Sell
160
-1,439
-90% -$241K ﹤0.01% 12429
2023
Q1 		$201K Buy
1,599
+328
+26% +$73.8K ﹤0.01% 10171
2022
Q4 		$385K Buy
+1,271
New +$187K ﹤0.01% 8800
2022
Q2 		– Sell
-202
Closed -$23K – 13314
2022
Q1 		$23K Sell
202
-1,195
-86% -$140K ﹤0.01% 13208
2021
Q4 		$201K Sell
1,397
-919
-40% -$167K ﹤0.01% 11842
2021
Q3 		$507K Sell
2,316
-287
-11% -$60.8K ﹤0.01% 9825
2021
Q2 		$604K Buy
2,603
+785
+43% +$200K ﹤0.01% 9606
2021
Q1 		$547K Buy
1,818
+1,464
+414% +$524K ﹤0.01% 9479
2020
Q4 		$133K Sell
354
-146
-29% -$51.2K ﹤0.01% 10022
2020
Q3 		$154K Buy
+500
New +$191K ﹤0.01% 8984
2019
Q4 		– Sell
-131
Closed -$56K – 9344
2019
Q3 		$56K Buy
+131
New +$84.3K ﹤0.01% 8672
2019
Q2 		– Sell
-125
Closed -$156K – 9417
2019
Q1 		$156K Buy
+125
New +$143K ﹤0.01% 8367
2018
Q2 		– Sell
-103
Closed -$167K – 8988
2018
Q1 		$167K Buy
+103
New +$214K ﹤0.01% 7474

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Ken Griffin's CBIO Position: Q4 2025 in Review

Ken Griffin sold out of Crescent Biopharma (CBIO) in Q4 2025, closing a stake of 25,593 shares — an estimated $304K sold.

Ken Griffin first reported a position in CBIO in Q2 2017 and held it in 26 quarters. The position peaked at $23.4M in Q2 2018. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2025.

  • Ken Griffin reported no remaining Crescent Biopharma position as of Q4 2025 after selling out during the quarter.
  • Ken Griffin sold 25,593 Crescent Biopharma shares in Q4 2025, an estimated $304K.
  • Ken Griffin first reported a position in Crescent Biopharma in Q2 2017 and held it in 26 quarters.
  • Ken Griffin's Crescent Biopharma position peaked at $23.4M in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.